New Lancet correspondence questions clinical meaning of Alzheimer's amyloid drugs

A new correspondence in The Lancet argues that while amyloid-beta antibodies like lecanemab and donanemab do clear amyloid from the brain, their clinical benefit for Alzheimer's patients isn't "meaningful." Researchers point to pooled data from multiple trials showing little real-world improvement for individuals. It's a direct challenge to the approved drugs.